These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17276692)

  • 21. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease.
    Simpson JM; Gil-Mohapel J; Pouladi MA; Ghilan M; Xie Y; Hayden MR; Christie BR
    Neurobiol Dis; 2011 Feb; 41(2):249-60. PubMed ID: 20875859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Bailey CD; Rogers DA; Johnson GV; Hayden MR; Leavitt BR
    J Neurochem; 2005 Oct; 95(1):210-20. PubMed ID: 16181425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice.
    Brooks S; Higgs G; Janghra N; Jones L; Dunnett SB
    Brain Res Bull; 2012 Jun; 88(2-3):113-20. PubMed ID: 20460143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice.
    Wong BKY; Ehrnhoefer DE; Graham RK; Martin DDO; Ladha S; Uribe V; Stanek LM; Franciosi S; Qiu X; Deng Y; Kovalik V; Zhang W; Pouladi MA; Shihabuddin LS; Hayden MR
    Neurobiol Dis; 2015 Apr; 76():24-36. PubMed ID: 25583186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.
    Franciosi S; Ryu JK; Shim Y; Hill A; Connolly C; Hayden MR; McLarnon JG; Leavitt BR
    Neurobiol Dis; 2012 Jan; 45(1):438-49. PubMed ID: 21946335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.
    Menalled L; El-Khodor BF; Patry M; Suárez-Fariñas M; Orenstein SJ; Zahasky B; Leahy C; Wheeler V; Yang XW; MacDonald M; Morton AJ; Bates G; Leeds J; Park L; Howland D; Signer E; Tobin A; Brunner D
    Neurobiol Dis; 2009 Sep; 35(3):319-36. PubMed ID: 19464370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased metabolism in the R6/2 mouse model of Huntington's disease.
    van der Burg JM; Bacos K; Wood NI; Lindqvist A; Wierup N; Woodman B; Wamsteeker JI; Smith R; Deierborg T; Kuhar MJ; Bates GP; Mulder H; Erlanson-Albertsson C; Morton AJ; Brundin P; Petersén A; Björkqvist M
    Neurobiol Dis; 2008 Jan; 29(1):41-51. PubMed ID: 17920283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
    Slow EJ; Graham RK; Osmand AP; Devon RS; Lu G; Deng Y; Pearson J; Vaid K; Bissada N; Wetzel R; Leavitt BR; Hayden MR
    Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11402-7. PubMed ID: 16076956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.
    Hickey MA; Kosmalska A; Enayati J; Cohen R; Zeitlin S; Levine MS; Chesselet MF
    Neuroscience; 2008 Nov; 157(1):280-95. PubMed ID: 18805465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.
    Southwell AL; Franciosi S; Villanueva EB; Xie Y; Winter LA; Veeraraghavan J; Jonason A; Felczak B; Zhang W; Kovalik V; Waltl S; Hall G; Pouladi MA; Smith ES; Bowers WJ; Zauderer M; Hayden MR
    Neurobiol Dis; 2015 Apr; 76():46-56. PubMed ID: 25662335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease.
    Bartl S; Xie Y; Potluri N; Kesineni R; Hencak K; Cengio LD; Balazs K; Oueslati A; Parth M; Salhat N; Siddu A; Smrzka O; Cicchetti F; Straffler G; Hayden MR; Southwell AL
    Neurobiol Dis; 2024 Jan; 190():106376. PubMed ID: 38092268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model.
    Steventon JJ; Harrison DJ; Trueman RC; Rosser AE; Jones DK; Brooks SP
    J Huntingtons Dis; 2015; 4(2):149-60. PubMed ID: 26397896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mouse models of Huntington disease: variations on a theme.
    Ehrnhoefer DE; Butland SL; Pouladi MA; Hayden MR
    Dis Model Mech; 2009; 2(3-4):123-9. PubMed ID: 19259385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains.
    Ivandic BT; Mastitsky SE; Schönsiegel F; Bekeredjian R; Eils R; Frey N; Katus HA; Brors B
    Cardiovasc Res; 2012 Apr; 94(1):87-95. PubMed ID: 22308238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.
    Becanovic K; Pouladi MA; Lim RS; Kuhn A; Pavlidis P; Luthi-Carter R; Hayden MR; Leavitt BR
    Hum Mol Genet; 2010 Apr; 19(8):1438-52. PubMed ID: 20089533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease.
    Carroll JB; Southwell AL; Graham RK; Lerch JP; Ehrnhoefer DE; Cao LP; Zhang WN; Deng Y; Bissada N; Henkelman RM; Hayden MR
    Mol Neurodegener; 2011 Aug; 6():59. PubMed ID: 21854568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standardized experiments in mutant mice reveal behavioural similarity on 129S5 and C57BL/6J backgrounds.
    van de Lagemaat LN; Stanford LE; Pettit CM; Strathdee DJ; Strathdee KE; Elsegood KA; Fricker DG; Croning MD; Komiyama NH; Grant SG
    Genes Brain Behav; 2017 Apr; 16(4):409-418. PubMed ID: 27886459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reaching and grasping phenotypes in the mouse (Mus musculus): a characterization of inbred strains and mutant lines.
    Tucci V; Achilli F; Blanco G; Lad HV; Wells S; Godinho S; Nolan PM
    Neuroscience; 2007 Jul; 147(3):573-82. PubMed ID: 17574766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and phenotypic characterization of the novel mouse substrain C57BL/6N Korl with increased body weight.
    Choi KM; Jung J; Cho YM; Kim K; Kim MG; Kim J; Kim H; Shin HJ; Kim HD; Chung ST; Cho S; Chung MW
    Sci Rep; 2017 Oct; 7(1):14217. PubMed ID: 29079844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.